Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2019 02:00 ET | Source: Adaptimmune Therapeutics plc

Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

- Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 - - Clinical benefit in 13 out of 14 patients - - One RECIST response maintained for more than 9 months after...
November 06, 2019 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update

- Clinical responses with ADP-A2M4 in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out of 12 patients - - ADP-A2M4 granted Orphan Drug Designation for...
November 01, 2019 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will report financial results...
October 09, 2019 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

PHILADELPHIA and OXFORDSHIRE, United Kingdom and IRVINE, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer,...
October 01, 2019 08:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, announces the...
September 30, 2019 08:45 ET | Source: Adaptimmune Therapeutics plc

Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated...
September 09, 2019 08:00 ET | Source: Adaptimmune Therapeutics plc

United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the...
August 27, 2019 08:00 ET | Source: Adaptimmune Therapeutics plc; Noile-Immune Biotech, Inc.

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech,...
August 01, 2019 07:15 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update

- Started SPEARHEAD-1 clinical trial with ADP-A2M4 in synovial sarcoma and MRCLS patients – - Started low-dose radiation sub-study with ADP-A2M4 with the MD Anderson Cancer Center - - Started...
August 01, 2019 07:15 ET | Source: Adaptimmune Therapeutics plc

New Executive Team Announced at Adaptimmune

- Adrian Rawcliffe to assume CEO role from September 1, 2019 - - John Lunger promoted to Chief Patient Supply Officer from August 1, 2019, as Adaptimmune gears up for commercial delivery of products...